Eva Hellström-Lindberg

2.5k citations

22 papers · 987 indexed · h-index 12

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood disorders and treatments
- Hemoglobinopathies and Related Disorders

Papers in

Hematology 19
- Acute Myeloid Leukemia Research 17
- Multiple Myeloma Research and Treatments 3
- Hematopoietic Stem Cell Transplantation 3
Genetics 11
- Hemoglobinopathies and Related Disorders 5
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Anna Porwit‐MacDonald Ingunn Dybedal Martin Jädersten Ramin Tehranchi Scott Montgomery Robert B. Howe Jon‐Magnus Tangen Gunnar Grimfors
Journals: Blood (15 papers)Clinical Cancer Research (3 papers)Hematology (1 paper)Experimental Hematology (1 paper)Leukemia Research (1 paper)
Partner nations: Sweden United Kingdom United States

In The Last Decade

Eva Hellström-Lindberg

21 papers receiving 963 citations

Peers

Countries citing papers authored by Eva Hellström-Lindberg

Since Specialization

Citations

This map shows the geographic impact of Eva Hellström-Lindberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hellström-Lindberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hellström-Lindberg more than expected).

Fields of papers citing papers by Eva Hellström-Lindberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hellström-Lindberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hellström-Lindberg. The network helps show where Eva Hellström-Lindberg may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Hellström-Lindberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Hellström-Lindberg Line = papers co-authored together Eva Hellström-Lindberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML Clinical Cancer Research ·Andreas T. Björklund, Mattias Carlsten, Ebba Sohlberg, Lisa L. Liu, Trevor Clancy, Mohsen Karimi, Sarah Cooley, Jeffrey S. Miller, Monika Klimkowska, Marie Schaffer, Emma Watz, Kristina Wikström, Pontus Blomberg, Björn E. Wahlin, Marzia Palma, Lotta Hansson, Per Ljungman, Eva Hellström-Lindberg, Hans‐Gustaf Ljunggren, Karl‐Johan Malmberg	2018	141
2	Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis Blood ·Pierre Fenaux, Aristoteles Giagounidis, Alan F. List, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, L.E. Caraballo, Barry Skikne, Jamile M. Shammo, Consuelo del Cañizo	2011	2
3	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry Blood ·Louise de Swart, Alex Smith, Pierre Fenaux, Argiris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Čermák, Alfred A. Sehnaoui, Ulrich Germing, Marius MacKenzie, Odile Beyne‐Rauzy, Luca Malcovati, Reinhard Stauder, Jackie Droste, David Bowen, Théo de Witte	2010	7
4	Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA). Blood ·Valeria Santini, Pierre Fenaux, Ghulam J. Mufti, Eva Hellström-Lindberg, Lewis B. Silverman, Alan F. List, Steven D. Gore, John F. Seymour, Jay T. Backstrom, David R. McKenzie, C.L. Beach	2008	4
5	Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression Blood ·Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, Brian Farnham, James S. Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg	2008	1
6	Myelodysplastic Syndromes: An Historical Perspective Hematology ·Eva Hellström-Lindberg	2008	5
7	Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q) Blood ·Andrea Pellagatti, Eva Hellström-Lindberg, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo Giovanni Della Porta, Martin Jädersten, Sally Killick, Davendra Sohal, Amit Verma, Mario Cazzola, James S. Wainscoat, Jacqueline Boultwood	2008	0
8	Differential Expression of Genes Related to JAK-STAT Pathway Activation or Megakaryocyte Differentiation/Maturation in CD34+ Cells from Patients with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T). Blood ·Luca Malcovati, Daniela Pietra, Matteo Giovanni Della Porta, Andrea Pellagatti, Erica Travaglino, Emanuela Boveri, Anna Gallì, Elisa Rumi, Francesco Passamonti, Laura Cremonesi, M. Brufal, Earl Gerald Gregorio, Eva Hellström-Lindberg, James S. Wainscoat, Mario Cazzola	2007	1
9	Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy. Blood ·Michael Grövdal, Kaboré Inoussa, Anni Aggerholm, Petar Antunović, Jan Astermark, Per Bernell, Ricardo Infante B., Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik W. Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg	2007	5
10	Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome Clinical Cancer Research ·Michael Grövdal, Kaboré Inoussa, Anni Aggerholm, Petar Antunović, Jan Astermark, Per Bernell, Ricardo Infante B., Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik W. Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg	2007	38
11	Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF Blood ·Martin Jädersten, Scott Montgomery, Ingunn Dybedal, Anna Porwit‐MacDonald, Eva Hellström-Lindberg	2005	143
12	Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion. Blood ·Martin Jädersten, Andrea Pellagatti, Ann‐Mari Forsblom, 静夫吉本, Mats Merup, Jan Samuelsson, James S. Wainscoat, Jacqueline Boultwood, Eva Hellström-Lindberg	2005	2
13	Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations Clinical Cancer Research ·Ramin Tehranchi, Bengt Fadeel, 姚少雄, Ann‐Mari Forsblom, 静夫吉本, Martin Jädersten, Birger Christensson, Robert Hast, Robert B. Howe, Jan Samuelsson, Boris Zhivotovsky, Eva Hellström-Lindberg	2005	25
14	Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells Blood ·Göran Carlsson, Andrew A.G. Aprikyan, Ramin Tehranchi, David C. Dale, Anna Porwit, Eva Hellström-Lindberg, Jan Palmblad, Jan‐Inge Henter, Bengt Fadeel	2004	71
15	The WHO classification of MDS does make a difference Blood ·Robert B. Howe, Anna Porwit‐MacDonald, LiNa SONG, Ramin Tehranchi, Eva Hellström-Lindberg	2003	103
16	Involvement and functional impairment of the CD34+CD38−Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8 Blood ·Lars Nilsson, Ingbritt Åstrand‐Grundström, Kristina Anderson, Ingrid Arvidsson, Peter Hokland, David Bryder, Lars Kjeldsen, Bertil Johansson, Eva Hellström-Lindberg, Robert Hast, Sten Eirik W. Jacobsen	2002	119
17	High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD Leukemia Research ·Syed Shaker Hussaini, Eva Kimby, B. Björkstrand, Birger Christensson, Eva Hellström-Lindberg	2001	12
18	Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39 Experimental Hematology ·Zuzana Hassan, Bengt Fadeel, Boris Zhivotovsky, Eva Hellström-Lindberg	1999	23
19	Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients Blood ·Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin, Magnus Carlsson, Jan Carneskog, Inger Marie S. Dahl, Ingunn Dybedal, Gunnar Grimfors, Lena Kanter‐Lewensohn, Olle Linder, 伊藤和江, Eva Löfvenberg, Herman Nilsson‐Ehle, Jan Samuelsson, Jon‐Magnus Tangen, Ingemar Winqvist, Gunnar Öberg, Anders Österborg, Åke Öst	1998	219
20	A Combination of Granulocvte Colonv-Stimulating Factor and Erythiopoietin may Synergistically Improve the Anaemia in Patients with Myelodysplastic Syndromes Leukemia & lymphoma ·Eva Hellström-Lindberg, Gunnar Birgegård, Magnus Carlsson, Jan Carneskog, Macan Aria Parsa, Ingunn Dybedal, Gunnar Grimfors, K. Merk, Jon‐Magnus Tangen, Ingemar Winqvist, John January	1993	52

About Eva Hellström-Lindberg

Eva Hellström-Lindberg is a scholar working on Hematology, Genetics, Oncology, Immunology and Physiology, having authored 22 papers that have together received 987 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (17 papers), Hemoglobinopathies and Related Disorders (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Neutropenia and Cancer Infections (3 papers), Erythrocyte Function and Pathophysiology (3 papers), Multiple Myeloma Research and Treatments (3 papers), Histone Deacetylase Inhibitors Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). The work is most often cited by research in Hematology (761 citations), Genetics (320 citations), Immunology (229 citations), Emergency Medicine (99 citations) and Oncology (225 citations). Eva Hellström-Lindberg has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Anna Porwit‐MacDonald, Ingunn Dybedal, Martin Jädersten, Ramin Tehranchi, Scott Montgomery, Robert B. Howe, Jon‐Magnus Tangen, Gunnar Grimfors, Magnus Carlsson and Ingemar Winqvist. Their work appears in journals such as Blood, Clinical Cancer Research, Hematology, Experimental Hematology and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact